Quantcast

Phase 2a Clinical Study Data of AJM300, Oral alpha 4 Integrin Antagonist, Will Be Presented in Digestive Disease Week 2014

April 16, 2014

TOKYO, April 16, 2014 /PRNewswire/ — Ajinomoto Pharmaceuticals Co., Ltd. announced on April 16 that the abstract of phase 2a clinical study data of an oral alpha 4 integrin antagonist, development code AJM300, has been accepted for presentation at the Digestive Disease Week 2014 (May 3 – 6 in Chicago, USA). The contents of data will be presented at the beginning of Joint Presidential Plenary Session collaborated by the American Society for Gastrointestinal Endoscopy and the American Gastroenterological Association.

- Study data to be presented (Presentation date / time: USA Eastern time zone)

    Abstract No.: 370

    Title:                      AJM300, an Oral alpha 4
                                Integrin Antagonist, for
                                Active

                                Ulcerative Colitis: a
                                Multicenter, Randomized,
                                Double-Blind, Placebo-
                                Controlled* Phase 2A
                                Study

    Presentation date / time:   May 4, 2014, 1:36-1:46
                                PM, Oral presentation

*Randomized double-blind, placebo-controlled study
Randomized double-blind, placebo-controlled study is a method of study to objectively evaluate the efficacy of medicine. In the study, neither investigators nor patients know which the patient takes a placebo (a mimic preparation that looks like a study drug but contains no active ingredient) or the study drug.

About Ajinomoto Pharmaceuticals Co., Ltd.
Representative Director,President & CEO: Takashi Nagamachi
Headquarters, Chuo-ku, Tokyo

Contact:
Hajime Ito
Corporate Planning Dept
Ajinomoto Pharmaceuticals Co., Ltd.
Tel: +81-3-6280-9802
e-mail: contact_ajis@ajinomoto.com



SOURCE Ajinomoto Pharmaceuticals Co., Ltd.


Source: PR Newswire



comments powered by Disqus